← Research library

Suprefort: clinical report on a tissue-derived preparation

Comparison in people · 2006

What was studied
59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
Main finding
In the diabetes subgroup, two-hour glucose was 7.0 mmol/L with Suprefort versus 9.4 mmol/L with usual care. Pancreatic enzyme changes in the separate pancreatitis subgroup were reported as trends.

Glucose two hours after challenge, type 2 diabetes subgroup · 7.0 ± 0.8 mmol/L with Suprefort versus 9.4 ± 0.5 mmol/L with usual care. · Table 3 marks p < 0.05 versus usual care.

Reported findings and study design

The group table lists 22 treated and 17 controls with type 2 diabetes, and 12 treated and 8 controls with chronic pancreatitis. The diabetes section describes one 10 mg capsule twice daily before meals for 10 days (20 mg/day). The general methods describe one or two 10 mg capsules twice daily for 15 days (20–40 mg/day).

Population or model 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.

Results · Russian Medical Center report, PDF pages 74–76, Tables 1–3
MeasureResultComparison, timing and statistics
Glucose two hours after challenge, type 2 diabetes subgroup7.0 ± 0.8 mmol/L with Suprefort versus 9.4 ± 0.5 mmol/L with usual care.Table 3 marks p < 0.05 versus usual care.
Fasting glucose, type 2 diabetes subgroup5.8 ± 0.3 versus 6.6 ± 0.4 mmol/L. Baseline values were 7.9 ± 1.1 and 8.2 ± 0.9 mmol/L respectively.The report marks significance against baseline for each arm.

Group sizes are from Table 1. Allocation methods, changes to other medications and the short follow-up limit attribution.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • Random allocation is asserted for the pancreatitis comparison without a method. Changing glucose-lowering co-treatment complicates attribution. This is not evidence for stopping diabetes medication.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Source details

Institute report — commercial reproduction

Russian Medical Center report, methods and Tables 1–3, PDF pages 74–76.

Sources checked

Citation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Human comparative studyRussian-language source

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution). Suprefort: clinical report on a tissue-derived preparation Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards